Local News

• Millipore welcomes new Bioscience Division President  Millipore Corporation officially welcomes Jon DiVincenzo as President of its Bioscience Division and member of its Corporate Executive Committee. Mr. DiVincenzo assumed his new role on January 1, 2009, succeeding Dominique Baly, who left Millipore at the end of December.
  Millipore Corporation January 08, 2009  
• Howard Feldman joins Bristol-Myers Squibb as vice president and therapeutic area head  Bristol-Myers Squibb announced that Dr. Howard Feldman has joined the company's Research and Development organization as vice president and therapeutic area head, Global Clinical Research, Neuroscience.
  Bristol-Myers Squibb Company January 08, 2009  
• Covidien receives FDA clearance to market SILS(TM) Port Multiple Instrument Access Port  Covidien announced that its Surgical Devices business unit has received 510(k) clearance from the U.S. Food and Drug Administration to market the Covidien SILS(TM) Port Multiple Instrument Access Port for laparoscopic surgeries through a single incision.
  Covidien Ltd. January 08, 2009  
• Infinity announces completion of second equity investment by Purdue  Infinity Pharmaceuticals announced that its shareholders have voted to approve the issuance and sale of $30 million in Infinity common stock and warrants to Purdue Pharma L.P. and Purdue Pharmaceutical Products L.P.
  Infinity Pharmaceuticals, Inc. January 08, 2009  
• Researchers select Bruker 12 Tesla FTMS and maXis(TM) UHR-TOF technologies  Bruker Daltonics announced that the laboratory of Professor Michael Gross at Washington University in St. Louis has ordered a package consisting of a Bruker 12 Tesla FTMS and a maXis UHR-TOF, primarily for applications in top-down proteomics.
  Bruker Corporation January 08, 2009  
• Palomar and Q-MED AB terminate international distribution agreement  Palomar Medical Technologies announced the termination of its international distribution agreement with the Swedish company Q-MED AB, a leading biotech/medical device company based in Uppsala, Sweden.
  Palomar Medical Technologies, Inc. January 08, 2009  
• Liquidia, Abbott team up to target cancer  One of the biggest challenges of cancer treatment is delivering drugs in a way that kills the bad cells without doing too much damage to healthy cells. The CEO of Liquidia Technologies hopes that a deal announced between his company and Abbott Laboratories will help to address that problem.
  Triangle Business Journal January 07, 2009  Jeff Drew
• Positive step for drug from engineered goat  In a surprise move, it seems likely the first genetically engineered animal approved for commercial use won't be a fast-growing salmon, as was expected, but a goat that produces an anti-clotting drug in its milk.
  USATODAY January 07, 2009  Elizabeth Weise
• FDA issues a Complete Response Letter for Lilly's olanzapine LAI  Eli Lilly and Company announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults.
  Eli Lilly and Company January 07, 2009  
• Acusphere announces receipt of NASDAQ panel decision to delist common stock  Acusphere announced that it has received notification that the NASDAQ Listing Qualifications Panel has determined to delist the Company's common stock from The NASDAQ Stock Market, effective with the open of business on Friday, January 9, 2009.
  Acusphere, Inc. January 07, 2009  

   (next 10 articles)